文献速递甲状腺疾病

碘塞罗宁治疗患者的死亡与不良事件风险:多源系统综述与荟萃分析

Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该多源系统综述与荟萃分析评估了碘塞罗宁(LT3)的安全性问题。研究检索了PubMed、英国黄卡计划及美国FAERS数据库,纳入52项研究(21项RCT、4项队列、27例病例报告)。结果显示规范使用LT3与死亡或严重不良事件风险增加无关,但需更多研究补充现有数据。

要点

  • 规范使用LT3未增加死亡或严重不良事件风险。
  • RCT荟萃分析显示联合治疗与单药治疗不良事件风险相似。
  • 队列研究显示LT3使用者死亡率降低,但房颤、心衰、卒中风险无显著增加。

核心结论

  • 规范使用LT3与死亡或严重不良事件风险增加无关。
  • 需要更多研究来补充现有数据。

研究设计与样本

  • 多源系统综述与荟萃分析,检索PubMed、英国黄卡计划及美国FAERS数据库。
  • 共纳入52项研究,包括21项随机对照试验、4项队列研究和27例病例报告。

主要发现

  • LT3相关不良事件仅见于未规范使用LT3或药房配制错误的情况。
  • 英国黄卡计划中LT3与LT4的不良事件严重程度相似。
  • FAERS数据库的不比例分析未显示LT3安全性信号增加。
  • RCT荟萃分析(n=2128)显示联合治疗与单药治疗的不良事件风险相似(RR 1.22,95%CI 0.66-2.25)。

临床怎么用

  • 在规范使用的前提下,LT3联合治疗未显示增加死亡或严重不良事件风险。
  • 临床决策时可参考本荟萃分析结果,但需注意个体化评估。

局限性

  • 需要更多研究来补充现有数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although some patients with hypothyroidism prefer combination therapy with liothyronine (LT3) and levothyroxine (LT4), the safety of LT3 remains unresolved. OBJECTIVE: We undertook a multisource systematic review and meta-analysis of LT3 safety. DATA SOURCES: We searched PubMed for articles relating to death, adverse events (AEs), and cardiovascular outcomes in LT3 users. We also searched AEs data in the UK Yellow Card scheme and US Food and Drug Administration Adverse Reporting System (FAERS). DATA EXTRACTION: Data was extracted independently by 2 reviewers. Out of 1814 articles identified, 52 studies were selected, comprising 21 randomized controlled trials (RCTs), 4 cohort studies, and 27 case reports. Meta-analyses were conducted for adverse outcomes in RCTs and cohort studies of combination vs monotherapy. DATA SYNTHESIS: LT3-related AEs were only reported with unregulated LT3 use or pharmacy compounding errors. LT3 and LT4 showed similar adverse severity profiles in the Yellow Card scheme. Disproportionality analysis in the FAERS database showed no increased LT3 safety signals. A meta-analysis of RCTs (n = 2128) showed a similar AEs risk for combination vs monotherapy [relative risk (RR) 1.22, 95% confidence interval (CI) 0.66-2.25]. A cohort study meta-analysis (LT3 vs LT4-only users, n = 630 254) showed no increased risk of atrial fibrillation (RR 1.10, 95% CI 0.74-1.63), heart failure (RR 1.54, 95% CI 0.95-2.47), or strokes (RR 0.86, 95% CI 0.11-6.75), but reduced mortality risk was observed for LT3 (RR 0.70, 95% CI 0.62-0.78). CONCLUSION: Our findings are reassuring that regulated LT3 use is not associated with the risk of death or serious AEs. More studies are needed to supplement existing data.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bahl S, Taylor PN, Premawardhana LD, et al. Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2025. PMID: 40795305. doi:10.1210/clinem/dgaf449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。